Tyra Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Todd Harris
- Full Time Employees
- 87
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2656 State Street Carlsbad CA United States of America 92008
- IPO Date
- Sep 15, 2021
- CIK
- 0001863127
- Website
- tyra.bio
- Similar Companies
- Business
- Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting large opportunities in fibroblast growth factor receptor (FGFR) biology. Founded in 2018 and headquartered in Carlsbad, California, Tyra leverages its proprietary SNÅP platform for precision drug discovery aimed at overcoming acquired resistance to current cancer therapies. The company’s main products include TYRA-300, an oral selective FGFR3 inhibitor in Phase 2 development for treating FGFR3-positive solid tumors such as metastatic urothelial carcinoma and pediatric achondroplasia, TYRA-200, an oral FGFR1/2/3 inhibitor in clinical trials for FGFR2-driven intrahepatic cholangiocarcinoma and other advanced solid tumors, and TYRA-430, an oral FGFR4/3-biased inhibitor targeting FGF19+/FGFR4-driven cancers in ongoing clinical trials. Recent major developments include clearance by the U.S. FDA to proceed with a Phase 2 clinical trial of TYRA-300 for pediatric achondroplasia (BEACH301), coupled with positive interim clinical proof-of-concept results for TYRA-300 in metastatic urothelial carcinoma from the SURF301 study. The company is advancing multiple Phase 2 studies for TYRA-300, including SURF302 for intermediate-risk non-muscle invasive bladder cancer and BEACH301 for achondroplasia, alongside ongoing SURF201 Phase 1 studies for TYRA-200 and SURF431 for TYRA-430. Tyra Biosciences also completed a $200 million private placement financing in early 2024 to bolster its pipeline development and clinical trial progression. The company maintains a robust clinical pipeline with a focus on targeting resistance mechanisms in oncology and genetically defined conditions, supported by strategic investor backing from firms including RA Capital Management and Boxer Capital. Tyra operates primarily within the biotechnology industry’s precision oncology segment with a focus on large markets including oncology and rare genetic diseases. Its targeted therapy candidates are designed to address FGFR-driven cancers and skeletal dysplasia conditions. The company conducts its clinical and preclinical operations across the United States with a focus on advancing molecularly targeted therapies that improve patient outcomes through precision medicine. Tyra Biosciences remains publicly traded on the NASDAQ under the ticker symbol TYRA and continues to extend its clinical-stage footprint through systematic clinical trial progression and strategic capital raises.
Company News
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Moderate Buy” by Analysts
Algert Global LLC Buys 51,110 Shares of Tyra Biosciences, Inc. $TYRA
5AM Venture Management LLC Acquires Shares of 1,029,298 Tyra Biosciences, Inc. $TYRA
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
Tyra Biosciences to Participate in Upcoming Investor Conferences
AquaBounty Technologies (NASDAQ:AQB) versus Tyra Biosciences (NASDAQ:TYRA) Head to Head Analysis
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally